Eupraxia Pharmaceuticals Inc. (EPRX): EPS (Basic)
-$1.03
Year ended 2025-12-31
| Period ended | EPS (Basic) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$1.03 | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$0.76 | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$1.17 | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$0.96 | n/a | 2024-04-01, From 2022-01-01 |
EPS (Basic) at similar companies
| Company | Year ended | EPS (Basic) | Change YoY |
|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | -$1.03 | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $3.73 | -51.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $3.47 | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$0.05 | n/m |
| Eli Lilly & Co (LLY) | 2025-12-31 | $23.00 | +95.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.37 | -3.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $11.13 | +90.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.08 | +163.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $7.30 | +8.0% |
Compare EPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗